CYTK
Price
$30.10
Change
-$0.39 (-1.28%)
Updated
May 23, 12:06 PM (EDT)
Capitalization
3.64B
69 days until earnings call
IDYA
Price
$19.15
Change
-$0.00 (-0.00%)
Updated
May 22 closing price
Capitalization
1.64B
81 days until earnings call
Interact to see
Advertisement

CYTK vs IDYA

Header iconCYTK vs IDYA Comparison
Open Charts CYTK vs IDYABanner chart's image
Cytokinetics
Price$30.10
Change-$0.39 (-1.28%)
Volume$400
Capitalization3.64B
IDEAYA Biosciences
Price$19.15
Change-$0.00 (-0.00%)
Volume$2.11K
Capitalization1.64B
CYTK vs IDYA Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. IDYA commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (CYTK: $30.49 vs. IDYA: $19.15)
Brand notoriety: CYTK and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 57% vs. IDYA: 0%
Market capitalization -- CYTK: $3.64B vs. IDYA: $1.64B
CYTK [@Biotechnology] is valued at $3.64B. IDYA’s [@Biotechnology] market capitalization is $1.64B. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 4 TA indicator(s) are bullish while IDYA’s TA Score has 6 bullish TA indicator(s).

  • CYTK’s TA Score: 4 bullish, 4 bearish.
  • IDYA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а +2.16% price change this week, while IDYA (@Biotechnology) price change was +10.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.67%. For the same industry, the average monthly price growth was +2.73%, and the average quarterly price growth was -2.78%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+0.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($3.64B) has a higher market cap than IDYA($1.64B). IDYA YTD gains are higher at: -25.486 vs. CYTK (-35.193). IDYA has higher annual earnings (EBITDA): -356.46M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. IDYA (693M). IDYA has less debt than CYTK: IDYA (26M) vs CYTK (791M). CYTK has higher revenues than IDYA: CYTK (19.2M) vs IDYA (7M).
CYTKIDYACYTK / IDYA
Capitalization3.64B1.64B223%
EBITDA-513.62M-356.46M144%
Gain YTD-35.193-25.486138%
P/E RatioN/AN/A-
Revenue19.2M7M274%
Total Cash938M693M135%
Total Debt791M26M3,042%
FUNDAMENTALS RATINGS
CYTK vs IDYA: Fundamental Ratings
CYTK
IDYA
OUTLOOK RATING
1..100
5714
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
59
Fair valued
PROFIT vs RISK RATING
1..100
8066
SMR RATING
1..100
9944
PRICE GROWTH RATING
1..100
9163
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (59) in the null industry is somewhat better than the same rating for CYTK (100) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than CYTK’s over the last 12 months.

IDYA's Profit vs Risk Rating (66) in the null industry is in the same range as CYTK (80) in the Biotechnology industry. This means that IDYA’s stock grew similarly to CYTK’s over the last 12 months.

IDYA's SMR Rating (44) in the null industry is somewhat better than the same rating for CYTK (99) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than CYTK’s over the last 12 months.

IDYA's Price Growth Rating (63) in the null industry is in the same range as CYTK (91) in the Biotechnology industry. This means that IDYA’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for IDYA (100) in the null industry. This means that CYTK’s stock grew significantly faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKIDYA
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
66%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 23 days ago
78%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
77%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SFSLX25.51N/A
N/A
1919 Financial Services C
VIGAX209.68N/A
N/A
Vanguard Growth Index Admiral
GSVCX14.48N/A
N/A
Goldman Sachs Large Cap Value C
MEFZX18.51N/A
N/A
MassMutual Mid Cap Growth I
CVMCX18.26N/A
N/A
Calvert Emerging Markets Equity C